Russian Heart Failure Journal 2015year Diagnostic significance of biological markers in chronic heart failure with preserved left ventricular ejection fraction

To access this material please log in or register

Register Authorize

Diagnostic significance of biological markers in chronic heart failure with preserved left ventricular ejection fraction

Bazaeva E. V., Myasnikov R. P., Metelskaya V. A., Boytsov S. A.
Federal State Budgetary Institution, "National Research Center for Preventive Medicine" of the RF Ministry of Health Care, Petroverigsky Per. 10, Bld 3, Moscow 101990

Keywords: diagnostics, preserved ejection fraction, CHF

DOI: 10.18087/rhfj.2015.1.2038

In the recent 15 years, the classic approach to diagnosing CHF provides for division into systolic and diastolic forms. Diastolic CHF is associated with signs of impaired relaxation and filling, loss of elasticity, and increased rigidity of LV. Such cases imply HF with preserved LV EF (HF-PLVEF). This group includes patients with normal (>50%) or practically unchanged (40–50%) LV EF; however the life prognosis for such patients has been shown to be worse that for patients with LV EF >50%. A reason for including patients with LV EF 40–50% or higher into the group with diastolic CHF is that their prognosis is considerably better than for patients with systolic CHF. Mechanisms of HF-PLVEF development are heterogeneous and understudied. HF-PLVEF has been suggested to be induced not only by impaired LV compliance but also by complex biochemical processes affecting cardiomyocytes and myocardial interstitium. Clinical manifestations of CHF are not sufficiently specific, and EchoCG not always detects significant disorders of the LV diastolic function. Therefore, in suspected HF-PLVEF, measurement of blood biomarkers can be used as an alternative diagnostic approach, since their concentrations increase in organic damage of the heart. This review discusses the place and role of biological markers in diagnostics of HF-PLVEF.
  1. Diagnosis of the working group on heart failure of the European society of cardiology. Increasing awareness and improving the ma­na­gement of heart failure in Europe: the IMPROVEMENT of HF initiative. Eur J Heart Fail. 1999 Jun;1 (2):139–44.
  2. Taylor CJ, Roalfe AK, Iles R, Hobbs FD. Ten-year prognosis of heart failure in the community: follow-up data from the Echocardiographic Heart of England Screening (ECHOES) study. Eur J Heart Fail. 2012 Feb;14 (2):176–84.
  3. Rosamond W, Flegal K, Friday G et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007 Feb 6;115 (5):169–71.
  4. Neumann T, Biermann J, Erbel R et al. Heart failure: the commo­nest reason for hospital admission in Germany: medical and economic perspectives. Dtsch Arztebl Int. 2009 Apr;106 (16):269–75.
  5. Беленков Ю. Н., Фомин И. В., Мареев В. Ю. и др. Первые результаты Российского эпидемиологического исследования по ХСН. Журнал Сердечная Недостаточность. 2003;4 (1):26–30.
  6. Агеев Ф. Т., Даниелян М. О., Мареев В. Ю. и др. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА–О–ХСН). Журнал Сердечная Недостаточность. 2004;5 (1):4–7.
  7. Агеев Ф. Т., Беленков Ю. Н., Фомин И. В. и др. Распростра­ненность хронической сердечной недостаточности в Европей­ской части Российской Федерации – данные ЭПОХА–ХСН. Журнал Сердечная Недостаточность. 2006;7 (1):112–5.
  8. Мареев В. Ю., Даниелян М. О., Беленков Ю. Н. Сравнительная характеристика больных с ХСН в зависимости от величины ФВ по результатам Российского многоцентрового исследования ЭПОХА–О–ХСН: снова о проблеме ХСН с сохранной систолической функцией левого желудочка. Журнал Сердечная Недостаточность. 2006;7 (4):164–71.
  9. Cowie MR, Fox KF, Wood DA et al. Hospitalization of patients with heart failure: a population-based study. Eur Heart J. 2002 Jun;23 (11):877–85.
  10. McAlister FA, Teo KK, Taher M et al. Insights into the contemporary epidemiology and outpatient management of congestive heart failure. Am Heart J. 1999 Jul;138 (1 Pt 1):87–94.
  11. Hogg K, Swedberg K, McMurray J. Heart Failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol. 2004 Feb 4;43 (3):317–27.
  12. Peach MJ. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol Rev. 1977 Apr;57 (2):313–70.
  13. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Журнал Сердечная Недостаточность. 2013;14 (7):379–472.
  14. Hammerer-Lercher A, Collinson P, van Dieijen-Visser MP et al. Do laboratories follow heart failure recommendations and guidelines and did we improve? The CARdiac MArker Guideline Uptake in Europe (CARMAGUE). Clin Chem Lab Med. 2013 Jun;51 (6):1301–6.
  15. Tang WH, Francis GS, Morrow DA et al. National Academy of clinical biochemistry laboratory medicine practice guidelines: utilization of cardiac biomarker testing in heart failure. Clin Biochem. 2008 Mar;41 (4-5):210–21.
  16. Grewal J, McKelvie R, Lonn E et al. BNP and NT-proBNP predict echocardiographic severity of diastolic dysfunction. Eur J Heart Fail. 2008 Mar;10 (3):252–9.
  17. Mannacio V, Antignano A, De Amicis V et al. B-type natriuretic peptide as a biochemical marker of left ventricular diastolic function: assessment in asymptomatic patients 1 year after valve replacement for aortic stenosis. Interact Cardiovasc Thorac Surg. 2013 Aug;17 (2):371–7.
  18. Jorge AJ, Freire MD, Ribeiro ML et al. Utility of B-type natriuretic peptide measurement in outpatients with heart failure with preserved ejection fraction. Rev Port Cardiol. 2013 Sep;32 (9):647–52.
  19. Hsich EM, Grau-Sepulveda MV, Hernandez AF et al. Relationship between sex, ejection fraction, and B-type natriuretic peptide le­vels in patients hospitalized with heart failure and associations with inhospital outcomes: findings from the get with the Guideline-Heart Failure Registry. Am Heart J. 2013 Dec;166 (6):1063–71.
  20. de Denus S, Lavoie J, Ducharme A et al. Differences in biomarkers in patients with heart failure with a reduced vs a preserved left ventricular ejection fraction. Can J Cardiol. 2012 Jan-Feb;28 (1):62–8.
  21. Mason JM, Hancock HC, Close H et al. Utility of biomarkers in the differential diagnosis of heart failure in older people: findings from the Heart Failure in Care Homes (HFinCH) diagnostic accuracy study. PLoS One. 2013;8 (1):e53560.
  22. Andrea R, Falces C, Sanchis L et al. Diagnosis of heart failure with preserved or reduced ejection fraction in a one-stop clinic. Aten Primaria. 2013 Apr;45 (4):184–92.
  23. Izumiya Y, Hanatani S, Kimura Y et al. Growth Differentiation Factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction. Can J Cardiol. 2014 Mar;30 (3):338–44.
  24. Stahrenberg R, Edelmann F, Mende M et al. The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur J Heart Fail. 2010 Dec;12 (12):1309–16.
  25. van Kimmenade RR, Januzzi JL, Ellinor PT et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006 Sep 19;48 (6):1217–24.
  26. Lok DJ, van der Meer P, de la Porte PW et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010 May;99 (5):323–8.
  27. De Boer RA, Lok DJ, Jaarsma T et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011 Feb;43 (1):60–8.
  28. Gopal DM, Kommineni M, Ayalon al. Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J Am Heart Assoc. 2012 Oct;1 (5):e000760.
  29. Cho HJ, Kim HS. Osteopontin: a multifunctional protein at the crossroads of inflammation, atherosclerosis, and vascular calcification. Curr Atheroscler Rep. 2009 May;11 (3):206–13.
  30. Soejima H, Irie A, Fukunaga T et al. Osteopontin expression of circulating T cells and plasma osteopontin levels are increased in relation to severity of heart failure. Circ J. 2007 Dec;71 (12):1879–84.
  31. Vittos O, Marta D, Serban M et al. Role of osteopontin and lipoprotein-associated phospholipase A2 as biomarkers in heart failure patients. Eur Heart J. 2012;33 (Abstr Suppl): 169.
  32. Tatemoto K, Hosoya M, Habata Y et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998 Oct 20;251 (2):471–6.
  33. Kleinz MJ, Skepper JN, Davenport AP. Immunocytochemical loca­lization of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept. 2005 Mar 30;126 (3):233–40.
  34. Taheri S, Murphy K, Cohen M et al. The effects of centrally admi­nistered apelin-13 on food intake, water intake and pituitary hormone release in rats. Biochem Biophys Res Commun. 2002 Mar 15;291 (5):1208–12.
  35. Tatemoto K, Takayama K, Zou M X et al. The novel peptide apelin lowers blood pressure via a nitric oxide dependent mechanism. Regul Pept. 2001 Jun 15;99 (2–3):87–92.
  36. Szokodi I, Tavi P, Foldes G et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res. 2002 Sep 6;91 (5):434–40.
  37. Chong KS, Gardner RS, Morton JJ et al. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail. 2006 Jun;8 (4):355–60.
  38. Wang M, Gupta RC, Rastogi S et al. Effects of acute intravenous infusion of apelin on left ventricular function in dogs with advanced heart failure. J Card Fail. 2013 Jul;19 (7):509–16.
  39. Negi SI, Jeong EM, Shukrullah I et al. Association of low plasma adiponectin with early diastolic dysfunction. Congest Heart Fail. 2012 Jul-Aug;18 (4):187–91.
  40. Fukuta H, Ohte N, Wakami K et al. Relation of plasma levels of adiponectin to left ventricular diastolic dysfunction in patients undergoing cardiac catheterization for coronary artery disease. Am J Cardiol. 2011 Oct 15;108 (8):1081–5.
  41. Fujita K, Maeda N, Sonoda M et al. Adiponectin protects against angiotensin II-induced cardiac fibrosis through activation of PPAR-alpha. Arterioscler Thromb Vasc Biol. 2008 May;28 (5):863–70.
  42. Fujioka D, Kawabata K, Saito Y et al. Role of adiponectin receptors in endothelin-induced cellular hypertrophy in cultured cardiomyocytes and their expression in infarcted heart. Am J Physiol Heart Circ Physiol. 2006 Jun;290 (6):H2409–16.
  43. Sam F, Duhaney TA, Sato K et al. Adiponectin deficiency, diastolic dysfunction, and diastolic heart failure. Endocrinology. 2010 Jan;151 (1):322–31.
  44. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005;23:337–66.
  45. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003 Jan 28;107 (3):499–511.
  46. Suzuki S, Takeishi Y, Niizeki T et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J. 2008 Jan;155 (1):75–81.
  47. Matsubara J, Sugiyama S, Nozaki T et al. Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol. 2011 Feb 15;57 (7):861–9.
  48. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006 Jan;52 (1):112–9.
  49. Balling L, Gustafsson F. Copeptin as a biomarker in heart failure. Biomark Med. 2014;8 (6):841–54.
  50. Kelly D, Squire IB, Khan SQ et al. C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remode­ling, and clinical heart failure in survivors of myocardial infarction. J Card Fail. 2008 Nov;14 (9):739–45.
Bazaeva E. V., Myasnikov R . P., Metelskaya V. A. et al. Diagnostic significance of biological markers in chronic heart failure with preserved left ventricular ejection fraction. Russian Heart Failure Journal. 2015;16 (1):43–51

To access this material please log in or register

Register Authorize
Ru En